Vivos Therapeutics (NASDAQ:VVOS) Posts Earnings Results, Beats Expectations By $0.15 EPS

Vivos Therapeutics (NASDAQ:VVOS) issued its quarterly earnings data on Monday. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.15, Zacks reports. Vivos Therapeutics had a negative net margin of 86.19% and a negative return on equity of 335.04%.

Vivos Therapeutics Stock Performance

Shares of NASDAQ:VVOS traded down $0.26 during trading on Monday, hitting $2.85. The company’s stock had a trading volume of 140,844 shares, compared to its average volume of 473,928. Vivos Therapeutics has a fifty-two week low of $1.91 and a fifty-two week high of $6.28. The stock’s 50-day moving average price is $3.78 and its two-hundred day moving average price is $3.61. The company has a market capitalization of $16.79 million, a PE ratio of -0.50 and a beta of 7.47.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.